Glucosylceramidase Beta (GBA) Genotyping

By Huw Morris
View Published Protocol

Output Details

Description

This protocol details the steps for GBA genotyping. This protocol has been adapted from the PRoBaND Clinical Consortium (incorporating methods described by Neuman et al., 2009 and Stone et al., 2000) and has been used for all publications for PRoBaND / Tracking Parkinson's describing clinical data and outcomes with respect to GBA status

Identifier (DOI)
10.17504/protocols.io.bzd7p29n
Tags
  • GBA (Glucocerebrosidase)
  • Genotyping
  • PCR
  • Sequencing
Team
Team Hardy
Program
Collaborative Research Network
Theme
PD Functional Genomics

Meet the Authors

  • Huw Morris

    Collaborating PI: Team Hardy, 

    University College London

Related Research

Lysosomal GCase (glucocerebrosidase) activity assay

Method to measure lysosomal GBA1 enzyme activity using 4-MUG substrate at low pH to minimize non-lysosomal GCase interference. GBA1 activity higher in purified lysosomes than whole cell extract, confirmed by CBE inhibitor abolishing 4-MUG hydrolysis.

View Protocol

(x6) GBA heterozygous and homozygous mutant fibroblast lines available to share

Cell lines deposited at ATCC used in a publication (10.1093/hmg/ddac233) include UCL-CTRL001, UCL-CTRL002, UCL-CTRL003, UCL-YCTRL001, UCL-E001K, UCL-N001S, and UCL-N002S, each with specific RRIDs.

View Lab Material

Lysosomal Glucocerebrosidase is needed for ciliary Hedgehog signaling: A convergent pathway to Parkinson’s disease

Mutations in LRRK2 and GBA1 are common in familial Parkinson’s disease. These mutations inhibit primary cilia formation, blocking Hedgehog signaling and reducing neuroprotective factors, contributing to PD pathogenesis.

View Article
View More Outputs